Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Compounds in development to combat hyperphosphataemia.

E Ritz1, O Hergesell

  • 1Medizinische Klinik I der Universität Heidelberg, Sektion Nephrologie, Bergheimerstr. 56A, 69115 Heidelberg, Germany. Prof.E.Ritz@T-online.de

Expert Opinion on Investigational Drugs
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De novo glomerulonephritis in patients during remission from Wegener's granulomatosis.

Clinical nephrology·1992
Same author

Reduced capillary density in the myocardium of uremic rats--a stereological study.

Kidney international·1992
Same author

Renal histology in polycystic kidney disease with incipient and advanced renal failure.

Kidney international·1992
Same author

The effect of uninephrectomy on progression of renal failure in autosomal dominant polycystic kidney disease.

Journal of the American Society of Nephrology : JASN·1992
Same author

Severe hemorrhagic complications from infection with nephropathia epidemica strain of Hantavirus.

Clinical nephrology·1992
Same author

Disturbed calcium metabolism in renal failure--pathogenesis and therapeutic strategies.

Kidney international. Supplement·1992
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

New iron-based phosphate binders offer a safe and effective alternative for dialysis patients. These compounds help manage hyperphosphataemia, reducing cardiovascular risks associated with traditional binders.

Area of Science:

  • Nephrology
  • Biochemistry
  • Pharmacology

Background:

  • Hyperphosphataemia in haemodialysis patients links to secondary hyperparathyroidism and increased cardiovascular mortality.
  • Phosphate removal during dialysis is insufficient, leading to a positive phosphate balance.
  • Classical phosphate binders (calcium- and aluminium-based) have significant side effects, including hypercalcaemia and aluminium intoxication.

Purpose of the Study:

  • To review experimental and clinical data on trivalent-iron (Fe-III) based phosphate binders.
  • To evaluate the efficacy and safety of Fe-III binders as alternatives to traditional phosphate-binding compounds.
  • To highlight the potential of Fe-III binders in managing hyperphosphataemia in dialysis patients.

Main Methods:

  • Review of existing experimental animal studies on Fe-III phosphate binders.

Related Experiment Videos

  • Analysis of clinical trial data from patients with preterminal renal failure and those on maintenance haemodialysis.
  • Assessment of data on phosphate binding capacity, serum phosphate reduction, and side effect profiles.

    • Main Results:

    • Fe-III based phosphate binders have demonstrated effectiveness in experimental models.
    • Clinical studies show Fe-III binders reduce urinary phosphate excretion and serum phosphate levels.
    • These binders present a promising alternative without the adverse effects of calcium- and aluminium-based agents.

    Conclusions:

    • Trivalent-iron (Fe-III) based phosphate binders are effective in controlling serum phosphate levels in dialysis patients.
    • Fe-III binders offer a potentially safer alternative, mitigating risks associated with hypercalcaemia and aluminium toxicity.
    • Further clinical data supports Fe-III binders as a viable and safe option for managing hyperphosphataemia in chronic kidney disease.